Developing new indications
for approved medicines in hematological malignancies
using a proprietary continuous delivery platform.

Targeted continuous delivery

We reimagine FDA-approved medicines and leverage our delivery system to establish new profiles. Our platform technology allows for lower drug exposure and the potential for improved efficacy.

Careers

We are building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers. Learn more about career opportunities at Starton.

News and Events

09/14/20

Keith Darragh Joins Starton Therapeutics as Chief Financial Officer

NEW YORK, N.Y., September 14, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology powering continuous delivery of approved drugs for novel indications, announced today…

09/09/20

Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors 

NEW YORK, N.Y., September 9, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced…